Update on the use of abatacept for the treatment of rheumatoid arthritis

Abstract

Abatacept is approved for the treatment of moderate-to-severe active rheumatoid arthritis (RA) patients with inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs), including methotrexate or a TNF antagonist, and can be used either as monotherapy or concomitantly with nonbiologic DMARDs. It can be administered either intravenously or subcutaneously. It has demonstrated to improve signs and symptoms of RA, physical function and health-related quality of life, and it inhibits radiographic progression of structural damage across a wide range of early and long-standing RA populations. The safety profile appears good and close to RA patients treated with nonbiologic DMARDs. Meta-analysis and real-world studies support these findings. This article reviews published data on clinical and radiographic efficacy as well as the safety of this drug, incorporating recent relevant information reported at scientific meetings.

Keywords::

• abatacept
• adverse events
• clinical efficacy
• pharmacokinetics
• radiographic progression
• safety

Acknowledgements

We thank Paz Hernanz, MD, from BMS, for her help in informing us of the latest data of symposia and international congresses related to recent clinical trials of abatacept.

Financial & competing interests disclosure

G Herrero-Beaumont has been an advisory board member of BMS, and has received grants and research support from BMS. S Castañeda has received honorary and research grants from BMS exceptionally. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.